Advertisement


Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement



Sep
17
Today In Oncology
FDA Grants Zanubrutinib Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
Survey Examines Oncology Clinician Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer
Inclusion of Women in Oncology Clinical Trials From 2000 to 2020
Atezolizumab Plus Chemotherapy in Patients With Advanced NSCLC and Brain Metastases
Almost Two-Thirds of Thoracic Oncologists Reported Using Telehealth for the First Time During the COVID-19 Pandemic
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside